[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-carcinoma":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,51,77,100,132,153,194,236,261,287,311,337,366,404,424,453,478,497,521,542,569],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628",false,"NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year",true,"ALL","45 Years","75 Years",{"count":20,"type":21},24000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[27,28,29,30,31,32,33,34,35,36,37],"Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma","RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":42},"2025-06-18",{"date":46,"type":21},"2029-06-30",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",38,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100641312","phase-2-clinical-trial-of-dn022150-combined-with-ag-chemotherapy-as-first-line-treatment-for-locally-advanced-or-metastatic-pancreatic-cancer-with-kras-g12d-mutation-100641312","NCT07656376","Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","Inclusion Criteria:\n\n1. Voluntarily signed informed consent form\n2. Age 18-75 years (inclusive), male or female, at the time of signing informed consent\n3. Life expectancy ≥ 12 weeks\n4. Subjects with confirmed KRAS G12D who have not received prior systemic antineoplastic therapy for advanced or metastatic pancreatic cancer\n5. ECOG score of performance status 0 \\~ 1\n6. At least one measurable lesion by RECIST v1.1 criteria\n7. Adequate organ function\n8. Effective methods of contraception during the study\n\nExclusion Criteria:\n\n1. Progression or other malignancy requiring treatment within 5 years prior to enrollment\n2. Prior targeted therapy for KRAS G12D\n3. With central nervous system metastasis\n4. Uncontrolled fluid accumulation\n5. Other anticancer therapy within 4 or 5 half-lives (whichever is shorter) before treatment\n6. Concomitant clinically significant cardiovascular disease\n7. Concurrent major acute or chronic infectious disease\n8. 4\\. Subjects who have undergone other major surgery other than diagnostic or biopsy, or are expected to undergo major surgery during the study;\n9. History of severe mental or psychological illness or drug abuse or a history of severe alcohol abuse\n10. Other situations not suitable for the study judged by the investigator","18 Years",{"count":59,"type":21},465,[61,62],"PHASE2","PHASE3","This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.",[65,36],"Pancreatic Cancer","NOT_YET_RECRUITING","2026-06-15",{"date":69,"type":42},"2026-06-18",{"date":71,"type":21},"2027-06-06",{"date":73,"type":21},"2029-05-08",{"name":75,"class":76},"Jiangxi Kvvit Pharmaceutical Co., Ltd.","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100340390","ultra-high-resolution-optical-coherence-tomography-in-detecting-micrometer-sized-early-stage-pancreatic-cancer-in-participants-with-pancreatic-cancer-100340390","NCT03711890","Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer","Imaging and Detection of Micrometer Sized Early Stage Pancreatic Cancer by Using Endoscopic Ultra-High Resolution Optical Coherence Tomography (OCT) Using Resected Pancreatic Specimen, a Pilot Study","Inclusion Criteria:\n\n* Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN\n* Immediate surgery cohort: Informed consent will be obtained\n* Adult patients undergoing pancreatic resection for a presumed IPMN\n\nExclusion Criteria:\n\n* Pregnant",{"count":85,"type":21},75,[24],"This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer. Ultra-high resolution optical coherence tomography may help to accurately identify pancreatic cancer in resected pancreatic specimens.",[36,89],"Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type","2026-06-11",{"date":67,"type":42},{"date":93,"type":42},"2019-03-26",{"date":95,"type":21},"2026-09-15",{"name":97,"class":98},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100641737","phase-1-a-study-of-clsp-5282-in-hla-a0301-positive-adult-patients-with-solid-tumors-sentinel-101-100641737","NCT07650357","A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)","SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation","Inclusion Criteria:\n\n* Adults at least 18 years of age on the day of signing informed consent.\n* Willing and able to provide written informed consent for the study.\n* Histologically or cytologically diagnosed, locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists.\n* Tumors must harbor the KRas G12V mutation confirmed by the site's local or preferred tissue or ctDNA testing platform in an accredited laboratory.\n* Patients must be HLA-A\\*03:01 positive by central assay.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Adequate hematological, renal and hepatic function.\n* Per Investigator judgement, patient is willing and able to complete study visits and\u002For procedures per the protocol and comply with study requirements for study participation.\n\nExclusion Criteria:\n\n* Patients who have received other KRas G12V directed cellular therapies or TCEs.\n* Patients may not be on other anticancer therapies at the time of the first dose of CLSP-5282. Exceptions upon agreement with Sponsor.\n* Any other primary malignancy within the 2 years prior to first dose of study treatment except for non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, breast), or prostate cancer in remission.\n* Patients who have not fully recovered from adverse events due to previous anticancer therapies\n* Patients with active infection requiring systemic antimicrobial therapy\n* Known primary malignant brain tumors, active central nervous system metastases and\u002For carcinomatous meningitis",{"count":108,"type":21},140,[110],"PHASE1","Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.",[113,114,36,115],"Advanced Solid Tumor","Non Small Cell Lung Cancer","Colorectal Cancer",[117,118,119,120,121],"T-Cell Engager","TCE","Clasp-5282","KRas G12V mutation","HLA A*03:01","2026-06-10",{"date":124,"type":42},"2026-06-16",{"date":126,"type":21},"2026-07",{"date":128,"type":21},"2029-07",{"name":130,"class":76},"Clasp Therapeutics, Inc.",4,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100536935","pancreatic-cancer-detection-consortium-pcdc-prospective-cohorts-100536935","NCT06271291","Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts","Inclusion Criteria:\n\n* PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:\n\n  * Age: 50 or older, plus at least one of the following:\n\n    * Mutation unknown or absent:\n\n      * 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;\n      * OR 2+ affected first degree relatives \\[(FDR), defined as blood related parents, siblings, or children\\]\n    * Known pathogenic\u002Flikely pathogenic (P\u002FLP) mutation in at least one of the following:\n\n      * CDKN2A\u002Fp16, Peutz-Jeghers syndrome (PJS) serine\u002Fthreonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)\n    * OR 1+ or second degree relative (SDR) with PDAC and a known P\u002FLP mutation in one or more of:\n\n      * ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53\n* HIGH-RISK OR WORRISOME PANCREATIC CYSTS:\n\n  * 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria\n\n    * High risk stigmata:\n\n      * Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas\n      * Enhancing mural nodule ≥ 5 mm\n      * Main pancreatic duct ≥ 10 mm\n    * Worrisome features:\n\n      * Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\\> 6 mm\n      * Cyst ≥ 3 cm\n      * Enhancing mural nodule \\\u003C 5 mm\n      * Thickened\u002FEnhancing cyst wall\n      * Main duct size 5-9 mm\n      * Pancreatitis\n      * Lymphadenopathy\n      * Increased CA 19-9\n      * Cyst growth rate ≥ 5 mm \u002F2 years\n\nExclusion Criteria:\n\n* Is unable to provide informed consent\n* Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)\n* Current or prior history of PDAC or total pancreatectomy\n* Is currently a prison inmate\n* Is not able to speak or read English",{"count":139,"type":21},30000,"OBSERVATIONAL","This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.",[36],"2026-05-29",{"date":145,"type":42},"2026-06-01",{"date":147,"type":42},"2024-12-12",{"date":149,"type":21},"2029-11-01",{"name":151,"class":98},"Mayo Clinic",9,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":99},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":161,"type":21},27,[61],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[165,166,167,27,28,168,29,169,170,171,172,173,174,175,176,33,34,177,178,179,180,181,35,36,182,37,183,184,185],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Primary Peritoneal Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":188,"type":42},"2026-05-18",{"date":190,"type":42},"2025-12-18",{"date":192,"type":21},"2026-12-18",{"name":151,"class":98},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":216,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100529338","phase-2-a-study-of-her3-dxd-in-subjects-with-locally-advanced-or-metastatic-solid-tumors-100529338","NCT06172478","A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for enrollment into the study:\n\n1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.\n2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \\>18 years old).\n3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:\n\n   Cutaneous (acral and non-acral) melanoma\n   1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma\n   2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \\[ICIs\\] \\[ie, anti-CTLA4, anti- LAG-3\\] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF\u002FMEK inhibitor therapy as well.\n\n      Squamous cell carcinomas of the head and neck\n   3. Squamous cell carcinoma of the head and neck (with a primary location of oral cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive or negative (as determined by local standard). Excludes tumor location in the nasopharynx, nasal cavity, paranasal sinuses, and unknown primary locations.\n   4. Disease progression after having received treatment with ≥1 and \\\u003C3 prior lines of systemic therapy in the unresectable recurrent or metastatic setting.\n\n      Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination with chemotherapy or other therapies). Must also have had disease progression on a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic setting or in the locally advanced setting with curative intent.\n\n      Gastric or GEJ adenocarcinoma\n   5. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry \\[IHC\\] 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   6. Disease progression after having received treatment with ≥2 prior lines of therapy that include PBC with or without anti-PD-1 therapy.\n\n      Ovarian Carcinoma\n   7. Pathologically documented high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n   8. Documented disease progression ≥4 weeks after the last dose of PBC and \\\u003C6 months of last dose of PBC in the advanced or metastatic setting. Prior use of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab soravtansine) is allowed.\n\n      Cervical Cancer\n   9. Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix.\n   10. Disease progression after having received ≥1 line of systemic therapy in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment and\u002For tissue factor directed ADC (tisotumab vedotin \\[TV\\]) per regional standard of care.\n\n       Endometrial Cancer\n   11. Pathologically or cytologically documented endometrial cancer (carcinoma of any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite instability (MSI) or mismatch repair (MMR) status.\n   12. Documented disease progression after having received ≥1 prior line of therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Bladder Cancer\n   13. Pathologically or cytologically documented locally advanced\u002Funresectable or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. Small cell\u002Fneuroendocrine tumors are not allowed even if mixed histology.\n   14. Relapsed or progressed after treatment with ≥1 prior line of therapy (maximum of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor treatment for those who are eligible are allowed.\n\n       * Required treatments can be given in combination or sequentially\n       * Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy\n       * The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy\n       * Participants in the second-line setting who have previously received enfortumab vedotin and pembrolizumab in combination can be enrolled.\n\n       Esophageal Carcinoma\n   15. Pathologically or cytologically documented esophageal squamous cell carcinoma.\n   16. Must have documented disease progression after having received 2 prior lines of therapy including previous PBC with or without an anti-PD-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Pancreatic Carcinoma\n   17. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma.\n   18. Relapsed or disease progression after having received 1 prior line of systemic therapy in the locally advanced\u002Fmetastatic setting.\n\n       Prostate Cancer\n   19. Pathologically or cytologically documented unresectable locally advanced or metastatic castration-resistant prostate cancer (CRPC).\n   20. Adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.\n   21. Surgically or medically castrated, with testosterone levels of \\\u003C50 ng\u002FdL.\n   22. Documented objective progression as determined by radiographic progression for subjects with measurable disease after androgen deprivation.\n   23. Relapsed or disease progression after having received treatment with ≥1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide, or darolutamide.\n   24. Relapsed or disease progression after having received ≥1 cytotoxic chemotherapy regimen that included a taxane.\n\n       Gastric Cancer 2L\n   25. Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression (IHC 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   26. Disease progression after having received treatment with only 1 prior line of systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive, treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line setting is allowed.\n\n   Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement, BRAF V600E mutation, EGFR-activating mutations \\[exon 19 deletion or L858R mutation\\], EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14 skipping mutation, NTRK 1\u002F2\u002F3 gene fusion, RET rearrangement, or ROS1 rearrangement). New testing for these genomic alterations is not required for Screening.\n\n   cc. Relapsed or disease progression after receiving only anti-PD-(L)1 and PBC (ie, platinum doublet) administered in combination or sequentially for metastatic disease.\n\n   Breast Cancer dd. Pathologically documented breast cancer that is assessed as HER2 negative (IHC2+\u002FISH-, IHC1+, or IHC0 per ASCO\u002FCAP guidelines), and HR positive (either ER and\u002For PgR positive \\[ER or PgR ≥1%\\] per ASCO\u002FCAP guidelines). The HER2 and HR results must be from a tumor sample obtained in the metastatic setting.\n\n   ee. Participant must have received one line of chemotherapy for mBC, but not more than one line and must have a clinically or radiologically documented evidence of tumor progression on or after CDK 4\u002F6 inhibitor combined with endocrine therapy; previous treatments with phosphoinositide 3-kinase (PI3K) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, protein kinase B (PKB) inhibitors also known as AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed.\n4. Has ≥1 measurable lesion on CT or MRI as per RECIST v1.1 by investigator assessment. Prostate cancer participants with bone only disease may be eligible.\n5. Provides a pretreatment tumor tissue sample that meets 1 of the following collection requirements:\n\n   1. Tumor biopsy from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the tissue ICF (ARCHIVAL PRETREATMENT sample).\n\n      OR\n   2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of tissue ICF (FRESH PRETREATMENT sample)\n6. Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Has HER2-positive gastric cancer as classified by ASCO-CAP guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n2. Has nasopharyngeal cancer.\n3. Has mucosal or uveal melanoma.\n4. Has a history of (non-infectious) interstitial lung disease (ILD), that required corticosteroids, has current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n5. Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses\n6. Is receiving chronic systemic corticosteroids dosed at \\>10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.\n\n   Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.\n7. Had prior treatment with an anti-HER3 antibody and\u002For antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).\n8. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, except the following:\n\n   1. Adequately treated nonmelanoma skin cancer\n   2. Adequately treated intraepithelial carcinoma of the cervix\n   3. Any other curatively treated in situ disease\n9. Has any evidence of severe or uncontrolled diseases (eg, active bleeding diatheses, active serious infection) psychiatric illness\u002Fsocial situations, geographical factors, substance abuse, or other factors that, in the investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol\n10. Has previously received topoisomerase-1 inhibitors (e.g., irinotecan) treatment in the advanced or metastatic disease setting.",{"count":202,"type":21},740,[61],"This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \\[cutaneous\u002Facral\\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.",[113,178,206,207,35,208,209,210,211,36,212,213,214,215],"Head and Neck Cancer","Gastric Cancer","Cervical Cancer","Endometrial Cancer","Bladder Cancer","Esophageal Cancer","Prostate Cancer","Non-small Cell Lung Cancer (NSCLC)","Lung Cancer","Breast Cancer",[113,178,206,207,217,218,219,220,221,222,223,224,225,226,214,215],"Ovarian carcinoma","Cervical cancer","Endometrial cancer","Bladder cancer","Esophageal carcinoma","Pancreatic carcinoma","Prostate cancer","Patritumab Deruxtecan","HER3-DXd","U3-1402","2026-05-12",{"date":186,"type":42},{"date":230,"type":42},"2024-02-26",{"date":232,"type":21},"2028-10-10",{"name":234,"class":76},"Daiichi Sankyo",85,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":260},"100571667","phase-1-a-study-of-mgc028-in-participants-with-advanced-solid-tumors-100571667","NCT06723236","A Study of MGC028 in Participants With Advanced Solid Tumors","A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma that is refractory to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.\n* Participants in expansion cohorts must have either\n\n  * NSCLC adenocarcinoma with\n\n    * progression on or following anti-PD-1\u002FPD-L1 inhibitor, unless contraindicated\n    * progression on or following therapy for actionable mutations (e.g. EGFR or ALK mutations), if present\n    * no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.\n  * Pancreatic cancer\n\n    * following at least 1 systemic therapy\n    * no more than 2 prior lines of cytotoxic therapy for advanced or metastatic disease.\n  * Colorectal adenocarcinoma with\n\n    * Progression during or following standard therapy with a fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan unless contraindicated, refused or unavailable\n    * Progression after prior targeted treatment for CRC with actionable mutations such as EGFR, KRAS, BRAF and MSI- H\u002FdMMR, if present.\n    * No more that 2 lines of cytotoxic chemotherapy for advanced or metastatic disease\n    * No more than 4 lines of systemic regimens for advanced or metastatic disease\n* Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1.\n* Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue or be willing to undergo a biopsy procedure to obtain a fresh tumor sample.\n* Participants have acceptable physical condition and laboratory values.\n* Participants of childbearing potential must agree to use highly effective methods of birth control.\n* Participants must not be pregnant, planning to be pregnant, or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Active brain metastases or leptomeningeal metastases.\n* Prior stem cell, tissue, or solid organ transplant.\n* Another malignancy that required treatment within the past 2 years, with the exception of those with a negligible risk of metastasis or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score \\\u003C 6), or carcinoma in situ.\n* Active viral, bacterial, or fungal infection\n* Prior treatment with ADAM9 targeted agent for cancer.\n* Prior treatment with major surgery, mediastinal or lung radiation, vaccination with live virus vaccines, systemic cancer treatment, chimeric antigen receptor (CAR)-T cell therapy, or experimental treatment within 4 weeks of the start of study treatment.",{"count":244,"type":21},124,[110],"The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9.\n\nThe main question the study aims to answer is:\n\n* What types of side effects will participants experience when receiving MGC028?\n* Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors?\n\nParticipants will\n\n* Undergo screening procedures to determine eligibility\n* Receive study treatments initially every 3 weeks.\n* Have blood samples taken for routine and research tests\n* Have other examinations to check heart and lung function, and general health status\n* Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.\n* Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.",[248,249,250,36,29],"Advanced Solid Tumors","NSCLC Adenocarcinoma","Cholangiocarcinoma","2026-04-23",{"date":253,"type":42},"2026-04-27",{"date":255,"type":42},"2025-02-13",{"date":257,"type":21},"2027-04",{"name":259,"class":76},"MacroGenics",7,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100577541","phase-1-study-of-xnw28012-in-subjects-with-advanced-solid-tumors-who-failed-standard-treatments-100577541","NCT06799637","Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Efficacy of XNW28012 in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. For the dose escalation part: subjects with histologically or cytologically confirmed advanced and\u002For metastatic solid tumors who have failed the established standard anti-cancer therapies for a given tumor type or have been intolerant to such therapies.\n2. For the dose expansion part: subjects must have a histological or cytological diagnosis of progressive, locally advanced, and\u002For metastatic ovarian cancer, cervical cancer, pancreatic cancer, or colorectal cancer (CRC) who have failed the following anti-cancer therapies: Ovarian cancer, Cervical cancer, Pancreatic cancer, Colorectal cancer.\n3. Age ≥ 18 years old at the time of consent.\n4. Subjects must have at least 1 measurable lesion as defined per RECIST version 1.1 (for dose expansion part only).\n5. Subjects must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. ECOG status of 2 can be allowed if it is a result of disease progression and warrants discussion with the medical monitor.\n6. Subjects must have adequate organ function within 7 days prior to the first study drug administration, as indicated by the flaboratory values:\n7. Life expectancy of at least 12 weeks.\n8. Females of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n9. Non-sterile subjects must be willing to use a highly effective contraception (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized.\n10. Subjects are able to provide written informed consent, understand and are willing to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. A history of severe infusion reactions to other monoclonal antibodies\u002Fantibody drug conjugates (ADCs) or allergic reactions to any components of XNW28012.\n2. Any anti-tumor therapy within 28 days prior to the first dose, including but not limited to: small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drugs.\n3. Any active malignancy, with the exception of the specific types of cancers under investigation in this study and any locally recurring cancer that has been treated curatively .\n4. Have received a live vaccine within 4 weeks prior to the first dose of study drug. Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed; however, intranasal influenza vaccines will not be allowed if they are attenuated live vaccines.\n5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte \u002F macrophage colony stimulating factor support within 1 week before screening, or pegylated G-CSF within 2 weeks before screening.\n6. Subjects with toxicities (as a result of prior anti-cancer therapy) which have not improved to CTCAE grade ≤1 or stabilized, except those AEs not considered as a likely safety risk (e.g., alopecia).\n7. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack) ≤ 3 months prior to screening is allowed if stable.\n8. Any of the hematological risk factors:\n9. Subjects who are unwilling or unable to provide tumor tissue samples that meet the requirements for tissue factor (TF) expression testing.\n\n11\\. Clinically significant cardiovascular\u002Fcerebrovascular conditions. 12. Active ocular surface disease at screening, or subjects with any prior episode of cicatricial conjunctivitis.\n\n13\\. Any history of Toxic Epidermal Necrolysis (TEN) or Steven Johnson Syndrome. 14. Subjects who have undergone major surgery within 28 days prior to the first dose of study drug, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter \\[PICC\\] line).\n\nand so on.",{"count":269,"type":21},350,[110,61],"This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.",[248,36,273,274],"Ovarian Cancer","Cervical Cancers",[276],"XNW28012","2026-04-14",{"date":279,"type":42},"2026-04-15",{"date":281,"type":42},"2023-12-01",{"date":283,"type":21},"2026-12-31",{"name":285,"class":76},"Evopoint Biosciences Inc.",24,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":310},"100578141","phase-3-lanreotide-versus-placebo-before-surgery-to-prevent-a-surgical-complication-called-a-pancreatic-fistula-100578141","NCT06807437","Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula","Inclusion Criteria:\n\n* Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential\n* Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration\u002Frandomization date\n* Participants must not have a known history of a prior diagnosis of malabsorption syndrome\n* Participants must not have been treated with any somatostatin analogue within 180 days prior to registration\u002Frandomization\n* Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration\u002Frandomization\n* Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration\u002Frandomization\n* Participants must be ≥ 18 years old\n* Participants must have a complete documented medical history and physical exam within 28 days prior to registration\u002Frandomization\n* Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL\u002Fmin using the following Cockcroft -Gault formula within 60 days prior to registration\u002Frandomization\n* Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:\n\n  * Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed\n  * Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels\n  * Bromocriptine: Dose adjustments may be considered to account for absorption changes\n  * Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary\n  * CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure\n* In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy\n\n  * NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible\n* In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation\n* Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase \\[AST\\] \\> 190 U\u002FL or alanine aminotransferase \\[ALT\\] \\> 320 U\u002FL) within 60 days prior to registration\u002Frandomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable\n* Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)\n* Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen\n* Participants must be offered the opportunity to participate in specimen banking\n* Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study\n* NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n* For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations",{"count":295,"type":21},274,[62],"This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.",[36,299],"Pancreatic Neoplasm","2026-03-25",{"date":302,"type":42},"2026-03-31",{"date":304,"type":42},"2025-05-09",{"date":306,"type":21},"2027-11-01",{"name":308,"class":309},"SWOG Cancer Research Network","NETWORK",118,{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":99},"100477481","pilot-comparing-ctdna-idv-vs-spv-sample-in-pts-undergoing-biopsies-for-hepatobiliary-and-pancreatic-cancers-100477481","NCT05497531","Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Inclusion Criteria:\n\n* 18 years of age or older\n* Have or are undergoing work-up for hepatobiliary and\u002For pancreatic carcinoma (such as hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, pancreatic carcinoma)\n* Scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion\n* Must be able to provide a written informed consent\n\nExclusion Criteria:\n\n* Patients unable to hold reasonably still on a procedure table or hold their breath during imaging or needle passes\n* Patients with a gross body weight over 375 pounds (upper limit of the CT and angiography tables)\n* Patients with uncorrectable coagulopathy\n* Platelet count \\\u003C 30,000\u002Ful\n* International Normalized (INR) \\> 1.5\n* Patients with moderate to severe ascites who cannot undergo trans-jugular biopsy or sufficient drainage\n* No clear reachable target for percutaneous or trans-jugular biopsy\n* Patient who cannot have a peripheral blood draw for ctDNA",{"count":319,"type":21},15,[24],"This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.",[323,65,175,250,324,36],"Hepatobiliary Cancer","Ampullary Cancer",[326,327,65,323],"ctDNA","Circulating Tumor DNA","2026-02-23",{"date":330,"type":42},"2026-02-24",{"date":332,"type":42},"2022-09-07",{"date":334,"type":21},"2026-06",{"name":336,"class":98},"University of California, Irvine",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100620589","laryngopharyngeal-injury-after-endotracheal-intubation-under-general-anesthesia-100620589","NCT07359586","Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia","Incidence,Perioperative Risk Factors and Prognosis Associated With Laryngopharyngea Injury After Endotracheal Intubation Under General Anesthesia：A Retrospective Study","Inclusion Criteria:\n\n* Patients who underwent general anesthesia with tracheal intubation at the First Affiliated Hospital of Zhejiang University School of Medicine between October 2015 and September 2025\n* Patients who required otolaryngological consultation due to laryngopharyngeal complaints (including hoarseness, sore throat, cough, choking on drinking water, etc.) postoperatively\n* The surgical type was non-otolaryngological surgery\n\nExclusion Criteria:\n\n* Patients with a history of laryngopharyngeal lesions (e.g., granuloma, polyp, tumour, vocal cord paralysis\n* Patients with a preexisting tracheotomy\n* Patients requiring postoperative tracheotomy\n* Patients with incomplete medical records\n* Patients who underwent multiple surgeries but for whom the specific surgical episode responsible for the laryngopharyngeal complaints could not be identified",{"count":345,"type":21},1200,"This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine between October 1, 2015, and September 30, 2025, with a focus on issues related to postoperativelaryngopharyngeal complaints. Patients requiring otolaryngological consultation due to postoperative laryngopharyngeal complaints were identified via the case consultation system. Relevant patient data were collected through the Medison Anesthesia Information Management System and electronic medical record system, and telephone follow-up was conducted to assess patient prognosis. The primary outcome measures were the risk factors of postoperative hoarseness, while the secondary outcome measures included the incidence of postoperative hoarseness, the severity of vocal fold injury and its related risk factors. Additionally, the prognosis of patients and its related risk factors were evaluated. This study aims to reduce the incidence of perioperative laryngopharyngeal injury and provide a reference for the optimization of perioperative anesthetic regimens.",[207,348,349,36,250,350],"Hepatic Carcinoma","Pulmonary Carcinoma","Thyroid Carcinoma",[352,353,354,355],"hoarseness","Vocal cord injury","Incidence","Prognosis","2026-01-13",{"date":358,"type":42},"2026-01-22",{"date":360,"type":42},"2025-11-01",{"date":362,"type":21},"2026-12-25",{"name":364,"class":98},"Zhejiang University",2,{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":376,"conditions":377,"keywords":389,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":401,"locationsCount":403},"100545979","pancreatic-cancer-detection-consortium-100545979","NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",{"count":375,"type":21},2000,"This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[65,36,378,379,380,381,382,383,384,385,386,387,388],"Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Resectable","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III","Pancreatic Cancer, Adult","Pancreatic Cancer Non-resectable",[390,391,392,393,394],"Micro RNA","Exosome","Cell free","Early detection","Screening","2025-12-17",{"date":397,"type":42},"2025-12-19",{"date":399,"type":42},"2023-03-15",{"date":69,"type":21},{"name":402,"class":98},"City of Hope Medical Center",11,{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":99},"100522545","use-of-indocyanine-green-in-pancreas-surgery-100522545","NCT06084013","Use Of Indocyanine Green In Pancreas Surgery","Assessing the Role of Intraoperative Indocyanine Green Perfusion of the Transected Pancreas in Predicting Postoperative Pancreatic Leaks","Inclusion Criteria:\n\n* Participant scheduled for open pancreaticoduodenectomy or distal pancreatectomy for any diagnosis\n* Participant ≥ 18 years of age\n* Ability to understand nature and individual consequences of clinical trial\n* Written informed consent from participant or legally authorized representative\n* For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention\n* Participant needs to have an operative drain (any closed suction drain) after the procedure\n* Participants that do not require arterial reconstruction\n* Participants that require minor portal venous recounstructions including patch venoplasty\n\nExclusion Criteria:\n\n* Patients with previous history of adverse reaction to contrast dye, ICG or components of the dye\n* Prior pancreatectomy\n* Known diagnosis of hepatic insufficiency, hepatitis, liver fibrosis or cirrhosis, or chronic pancreatitis\n* Because this study focuses on hypoperfusion, patients will be excluded if in postoperative day 3-5 had any of the following: persistent SBP \\\u003C90 mmHg unresponsive to 1L crystalloid, unexpected ICU transfer, blood transfusion of \\>2 units intraoperatively or 1 postoperatively, vasopressor treatment or ACLS protocol initiation\n* Organ failure, anuria or NSQIP-identified complication will be reviewed by PI and attending surgeon and excluded\n* Patients that require arterial reconstruction as part of their procedures",{"count":412,"type":21},55,"This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.",[36],"2025-07-22",{"date":417,"type":42},"2025-07-25",{"date":419,"type":42},"2024-05-17",{"date":421,"type":21},"2026-02-28",{"name":423,"class":98},"OHSU Knight Cancer Institute",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":22,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":99},"100598092","phase-1-mesothelin-and-claudin-182-dual-target-car-t-therapy-in-advanced-pancreatic-cancer-100598092","NCT07066995","Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer","BAH2573-102","Inclusion Criteria:\n\n* Expected survival time ≥3 months;\n* Histologically or cytologically confirmed pancreatic adenocarcinoma that is advanced (unresectable or metastatic). Patients should have received, or be intolerant of, standard first-line therapy (e.g., gemcitabine\u002Fnab-paclitaxel, FOLFIRINOX) for advanced disease. A short course of current first-line therapy is allowed for the purpose of bridging to manufacturing, but evidence of disease progression on or after at least one line is required prior to infusion (for the dose-expansion phase, patients must have progressed on ≥1 prior systemic regimen).\n* ECOG Performance Status: 0 or 1 (fully active or restricted in strenuous activity but ambulatory).\n* Liver and kidney function, cardiopulmonary function meet the following requirements:\n* Creatinine ≤1.5×ULN; (2) Electrocardiogram showed no clinically significant abnormal bands;\n* Blood oxygen saturation \\>91% in non-oxygen state;\n* Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.\n* No serious mental disorders;\n* Can understand this test and has signed the informed consent.\n\nExclusion Criteria:\n\n* Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference value range; Hepatitis C virus (HCV) Antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) Antibody positive; Syphilis positive;\n* Serious heart disease, including but not limited to unstable angina, myocardial infarction or bypass or stent surgery (within 6 months prior to screening), congestive heart failure (NYHA classification ≥III), and severe arrhythmia;\n* Systemic diseases that are deemed unstable by researchers: including but not limited to severe liver, kidney, or metabolic diseases that require drug treatment;\n* Active or uncontrollable infections (except mild genitourinary and upper respiratory tract infections) that require systemic treatment within 7 days prior to administration;\n* Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partners plan pregnancy within 2 years after cell transfusion;\n* Patients who received CAR-T therapy or other gene-modified cell therapy before screening;\n* Participated in other clinical studies 1 month before screening;\n* Evidence of central nervous system invasion during subject screening;\n* Mental patients with depression or suicidal thoughts;\n* Situations considered unsuitable for inclusion by other researchers.","21 Years","90 Years",{"count":435,"type":21},60,[110,61],"Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy",[65,36,388,439],"Pancreatic Cancer Stage IV",[65,441,36,442,443],"claudin 18.2","CAR-T","Mesothelin","2025-07-04",{"date":446,"type":42},"2025-07-15",{"date":448,"type":42},"2025-04-29",{"date":450,"type":21},"2028-12-28",{"name":452,"class":98},"Essen Biotech",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":131},"100557495","phase-2-ceb-01-in-locally-resectable-pancreatic-cancer-100557495","NCT06538857","CEB-01 in Locally Resectable Pancreatic Cancer","Exploratory Clinical Trial to Assess Safety, Tolerability Efficacy and Pharmacokinetics of CEB-01 PLGA Membrane in Participants With Pancreatic Cancer.","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Participants must have a diagnosis of:\n\n   1. Lesion\u002Fs of histologically or cytologically confirmed de novo carcinoma, adenocarcinoma or ductal adenocarcinoma of the pancreas with only locally advanced disease, resectable or borderline resectable.\n   2. Histopathological confirmation of the diagnosis can be done during surgery by means of intraoperative biopsy as per clinical practice.\n\n   No need of preoperative biopsy.\n3. Participants previously treated with chemotherapy will be eligible if they have not had documented progressive disease during treatment.\n4. Participants must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion obtained by a validate imaging technique (i.e., magnetic resonance imaging (MRI), computed tomography (CT) scan, PET scan, ultrasounds or others) that can be accurately measured.\n5. Participants should have surgically removable lesion\u002Fs for what they will be submitted to a pancreatoduodenectomy.\n6. Normal renal function as defined by biochemical parameters as follows: creatinine ≤2 mg\u002Fdl or creatinine clearance ≥ 60 ml\u002Fmin\u002F1.73 m2.\n7. Haematological and cardiac function as defined by biochemical and haematological parameters as follows: haemoglobin (Hb) ≥10 g\u002FdL (with preoperative transfusion), platelets ≥80.000\u002Fmm3 with intraoperative transfusion, white blood cells (WBC) ≥3.000\u002Fmm3, neutrophil count ≥1.500\u002Fmm3.\n8. Liver function as defined by biochemical parameters as follows: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 4 times the upper limit of normality \\[ULN\\]. Recommended serum bilirubin for eligibility is bilirubin ≤ 10 mg\u002Fdl (or equivalent value in μmol\u002FL units). Preoperative biliary drainage to be done according to regular practice in each center. Patients in whom preoperative biliary drainage cannot be performed or biliary drainage was not completely effective, individualized decision to be made when bilirubin is ≥ 10 mg\u002Fdl (or equivalent value in μmol\u002FL units).\n9. Participants must have fully recovered from the acute toxic effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.\n10. Neoadjuvant chemotherapy is allowed in borderline and\u002For locally advanced cases borderline completed at least 4 weeks before surgery.\n11. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n12. Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.\n13. Men and women of childbearing potential must be willing to use adequate contraception throughout the study and for 6 months after surgery.\n14. The participant or a legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.\n\nExclusion Criteria:\n\n1. Other malignancies within past 2 years.\n2. R2 resections (macroscopic disease remains after surgery).\n3. Patients with homozygous UGT1A1 known to be at risk of increased toxicity with irinotecan and SN-38.\n4. Active bacterial, viral or fungal infection.\n5. Known history of active human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C or chronic liver disease. Testing is not required in the absence of clinical findings or suspicion.\n6. Impossibility of ensuring adequate follow-up.\n7. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.\n8. Contraindication to computed tomography scan (CT).\n9. Major surgery within 14 days prior to starting study drug or still in recovery after experiencing surgical complications; neither tumour biopsy nor central line insertion are considered a major surgery.\n10. Other relevant concomitant illnesses.\n11. Participants' status post-allogeneic stem cell transplant are not eligible.\n12. Participants with disease of any major organ system that would compromise their ability to withstand therapy.\n13. Pregnancy or lactation. Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.",{"count":461,"type":21},39,[61],"The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile.\n\nThe study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer",[36],[466,467,468],"Locally advanced disease","Resectable pancreatic cancer","Borderline resectable pancreatic cancer","2025-05-20",{"date":471,"type":42},"2025-05-23",{"date":473,"type":42},"2024-08-20",{"date":475,"type":21},"2028-09",{"name":477,"class":76},"CEBIOTEX",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":99},"100443779","pilot-study-of-pancreatic-cancer-screening-100443779","NCT05058846","Pilot Study of Pancreatic Cancer Screening","Inclusion Criteria:\n\nAbility to provide consent and willing, and able to comply with study procedures Ability to read and speak English\n\nGROUP I:\n\n* Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation\n* No strong family history of pancreatic cancer (defined as having \\>= 1 first-degree or second-degree relative with a history of pancreatic cancer)\n* Age \\>= 50 years old at time of consent.\n\nGROUP II:\n\n* Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation\n* Has strong family history of pancreatic cancer (defined as having \\>= 1 first-degree or second-degree relative with a history of pancreatic cancer)\n* Age \\>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family)\n\nExclusion Criteria:\n\n* Prior or active pancreatic cancer.\n* Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.",{"count":485,"type":21},250,"This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.",[36],"2025-04-30",{"date":490,"type":42},"2025-05-02",{"date":492,"type":42},"2022-01-20",{"date":494,"type":21},"2032-01-31",{"name":496,"class":98},"University of California, San Francisco",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100580158","effects-of-aromatherapy-with-essential-oils-on-anxiety-and-depression-in-perioperative-patients-with-pancreatic-cancer-100580158","NCT06833658","Effects of Aromatherapy with Essential Oils on Anxiety and Depression in Perioperative Patients with Pancreatic Cancer","Inclusion Criteria:\n\n* Meet diagnostic criteria in Chinese Anti-Cancer Association Guidelines for pancreatic cancer\n* Age ≥18 years\n* Contraception required, non-lactation period\n* Consistent with surgical indications\n* Surgical procedures: pancreaticoduodenectomy, extended pancreaticoduodenectomy, costocaudectomy, total pancreatectomy, subtotal pancreatectomy, pyloric-sparing pancreaticoduodenectomy\n* Elective surgery without preoperative radiotherapy or chemotherapy\n* Normal communication\n* Preoperative SAS score ≥50 or SDS score ≥53\n* Informed consent from subject or guardian\n\nExclusion Criteria:\n\n* History of mental illness or cognitive impairment\n* Severe liver\u002Fkidney disease, cardiopulmonary dysfunction, tumor recurrence\u002Fmetastasis\n* Allergy or intolerance to aromatic reagents, olfactory disorders, acute respiratory disease, serious complications (unstable vital signs, blood clotting disorders, irreversible metabolic diseases)\n* Poor compliance with study protocol or participation in similar studies\n* Termination due to disease treatment or condition changes\n* Withdrawal for personal reasons\n* Deemed unsuitable by investigator.",{"count":504,"type":21},156,[24],"The objective of this study is to investigate whether aromatherapy essential oils are effective in alleviating anxiety and depression in participants undergoing perioperative pancreatic cancer treatment. Researchers compared aromatherapy essential oils with a placebo (a substance that appears similar but contains no essential oils) to determine their efficacy in reducing anxiety and depression in these participants. Participants were required to undergo aromatherapy for 2 hours daily over a period of 15 days. Assessments of anxiety and depression were conducted one day before surgery, 14 days after surgery, and 42 days after surgery, with their scores recorded accordingly.",[36],[509,510,511,512],"Aromatherapy with essential oil intervention","pancreatic carcinoma","Anxiety","Depression","2025-02-18",{"date":515,"type":42},"2025-02-19",{"date":360,"type":21},{"date":518,"type":21},"2025-12-03",{"name":520,"class":98},"Peking University First Hospital",{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":99},"100522302","phase-2-ag-combined-with-immunotherapy-and-sbrt-in-patients-with-potentially-resectable-pancreatic-cancer-100522302","NCT06080854","AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","Efficacy and Safety of AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Age \\>= 18 years；\n2. Eastern Cooperative Oncology Group (ECOG) score of 0-1;\n3. Pancreatic cancer confirmed by histology or cytology;\n4. Potentially resectable pancreatic cancer documented by contrast enhanced CT (or MRI) scan;\n5. Hematological indexes: Neutrophil count \\>= 1.5 x 10\\^9\u002FL Hemoglobin \\>= 10g \u002F dl Platelet count \\>= 100 x 10\\^9\u002FL; Biochemical indicators: Total bilirubin \\\u003C= 1.5 x upper limit of normal value (ULN); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \\\u003C 1.5 x ULN; Creatinine clearance rate \\>= 60ml \u002F min.\n6. Participants of childbearing age need to take appropriate protective measures (contraceptive measures or other methods of birth control) before entering the group and during the test;\n7. Signed informed consent;\n8. Follow the protocol and follow-up procedures.\n\nExclusion Criteria:\n\n1. Have received systematic anti-tumor treatment.\n2. Previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (TA and TIS) or other malignant tumors that have received radical treatment (at least 5 years before enrollment).\n3. Active bacterial or fungal infection (\\> = level 2 of National Cancer Institute Common Toxicity Criteria (NCI-CTC), Version 3.0).\n4. Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases considered by researchers to be out of the group.\n5. Autoimmune diseases or immune defects who are treated with immunosuppressive drugs.\n6. Pregnant and lactating women. Pregnant women of childbearing age must be tested negative within 7 days before entering the group.\n7. Drug abuse, clinical or psychological or social factors make informed consent or research implementation affected.\n8. Allergic to programmed cell death protein-1 (PD-1) monoclonal antibody immunotherapy drugs.",{"count":529,"type":21},108,[61],"The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.",[36],"2023-10-06",{"date":535,"type":42},"2023-10-12",{"date":537,"type":21},"2023-11-10",{"date":539,"type":21},"2026-06-06",{"name":541,"class":98},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":543,"slug":544,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":99},"100343126","the-comparision-of-minimally-invasive-and-open-pancreaticoduodenectomy-for-pancreatic-cancer-100343126","NCT03747588","The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer","The Effect and Safety of Comparision Between Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer : A Randomized Prospective Trial","MIOPP","Inclusion Criteria:\n\n* Age: \\>18yr, \\\u003C75yr\n* Patients with pancreatic cancer or non-pancreatic cancers (biliary duct cancer or ampullary cancer) who underwent pancreatoduodenectomy\n* Preoperative imaging assessment is resectable or borderline resectable\n\nExclusion Criteria:\n\n* Benign tumors of the head of pancreas\n* Enhanced CT diagnosis revealed that the excess of SMV was more than 180 degrees, or distant metastasis.\n* conversion to laparotomy because of intraoperative difficulty",{"count":551,"type":21},100,[24],"Minimally invasive pancreaticoduodenectomy remains one of the most challenging abdominal procedures. Safety and feasibility remain controversial when comparing minimally-invasive with open pancreaticoduodenectomy, especially for malignant tumors.The aim of this study was to compare minimally invasive and open pancreatoduodenectomy for short-term outcomes and long-term follow-up in a randomized trial.",[36,555],"Surgery",[557,558,559],"minimally-invasive pancreaticoduodenectomy","open pancreaticoduodenectomy","pancreatic cancer","2022-09-30",{"date":562,"type":42},"2022-10-03",{"date":564,"type":42},"2018-12-01",{"date":566,"type":21},"2028-12-30",{"name":568,"class":98},"Peking Union Medical College Hospital",{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":576,"targetDuration":4,"studyType":22,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":99},"100346055","comparing-laparoscopic-and-open-surgery-for-pancreatic-carcinoma-100346055","NCT03785743","Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma","Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy for Pancreatic Carcinoma(TJDBPS07) a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 18 years and 75 years.\n2. Histologically confirmed PDAC or clinically diagnosed PDAC by an MDT without histopathologic evidence.\n3. Patients feasible to undergo both LPD and OPD according to MDT evaluations.\n4. Patients understanding and willing to comply with this trial.\n5. Provision of written informed consent before patient registration.\n6. Patients meeting the curative treatment intent in accordance with clinical guidelines.\n\nExclusion Criteria:\n\n1. Patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n2. Patients requiring left, central or total pancreatectomy or other palliative surgery.\n3. Preoperative American Society of Anaesthesiologists (ASA) score ≥ 4.\n4. History of other malignant disease.\n5. Pregnant or breast-feeding women.\n6. Patients with serious mental disorders.\n7. Patients treated with neoadjuvant therapy.\n8. Patients with vascular invasion and requiring vascular resection as evaluated by the MDT team according to abdominal imaging data.\n9. Body mass index \\> 35 kg\u002Fm2.\n10. Patients participating in any other clinical trials within 3 months.",{"count":577,"type":21},200,[24],"Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC. Minimally invasive surgery has been progressively developed, first with the advent of hybrid-laparoscopy and recently with the total laparoscopy surgeries, but a number of issues are currently being debated, including the superiority between total laparoscopic pancreaticoduodenectomy (TLPD)and the open pancreaticoduodenectomy (OPD). Studies comparing these two surgery techniques are merging and randomized controlled trials (RCT) are lacking but clearly required.\n\nMethods\u002Fdesign: TJDBPS07 is a multicenter prospective, randomized controlled, trial comparing TLPD and OPD in pancreatic cancers. A total of 200 patients with pancreatic cancer underwent PD will be randomly allocated to the TLPD group or OPD group with an enhanced recovery after surgery (ERAS) pattern. The trial's aim is to exploring the overall survival (OS), disease free survival (DFS) and quality of life. The duration of the entire trial is seven years including prearrangement, a presumably five-year follow-up and analyses.\n\nDiscussion: Despite the fact there are several RCTs comparing minimally invasive pancreaticoduodenectomy (MIPD) and Open approach or LPD versus OPD. This trial will be the first comparing TLPD and OPD in a large multicenter setting. TJDBPS01 trial is hypothesized to assess whether TLPD has superiority over OPD in recovery and other aspects.",[36,581,582],"Laparoscopic","Pancreaticoduodenectomy",[36,581,582,584],"Survival","2022-02-27",{"date":587,"type":42},"2022-03-02",{"date":589,"type":42},"2019-03-01",{"date":591,"type":21},"2027-05-01",{"name":593,"class":98},"Tongji Hospital"]